Project Grant R44CA302091
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $1.1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This federal Project Grant award of $1,340,987 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel CAR-enhancer platform. The platform seeks to augment the functionality and longevity of CAR T-cells, addressing the key challenge of limited durability of response in patients. The specific objectives of this 24-month project are to: 1) Optimize dosing and timing for administering the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Aerocytek, Inc. to develop an innovative approach for point-of-care autologous CAR-T cell manufacturing. The project aims to overcome current challenges in large-scale production and integration of CAR-T cell therapies by leveraging targeted microbubble-based technologies for T cell selection, activation, and transduction. This solution seeks to democratize the...
- This $314,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Persistence Therapeutics, Inc.'s novel "SynthNode" approach for CAR T cell therapy. The SynthNode is an implantable device the size of a dime that mimics the function of a lymph node, producing potent, antigen-specific CAR T cells that persist long-term for improved patient outcomes. This fast-track Phase I/II project will complete prototyping,...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,625.00 to Cellchorus Inc., a Houston-based company specializing in advanced cell analysis technologies, to develop a high-throughput platform for profiling the functional signatures of CAR T cells from patients with relapsed/refractory large B cell lymphoma (r/r LBCL). The goal is to create a scalable, AI-powered imaging technology called Time-lapse Imaging Microscopy in...
- This $1,124,607 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a Phase 2 multi-center clinical trial of a novel CD5 chimeric antigen receptor (CAR) T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The grant, awarded from July 1, 2025 to June 30, 2027, will validate the safety and efficacy of the improved MB-105 product, which has demonstrated promising results in...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...